Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines

Şamlı, Hale; Samli, Murat; Vatansever, Buse; Ardıçlı, Sena; Aztopal, Nazlıhan; Dinçel, Deniz; Şahin, Ahmet; Balcı, Faruk

doi:10.1007/s00345-018-2501-6

Cited by 25 publications

(12 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In line with our findings, a study published in 2019 demonstrated that miR100 was under-expressed in patients with low-grade tumors compared to the high-grade group; however, after multivariate analysis there was no statistical significance. 23 This behavior of worse prognosis was also identified by Samli et al 24 who showed an overexpression of miR100 in paclitaxel-resistant VCaP-R and DU145-R cells.…”

Section: Discussionsupporting

confidence: 60%

The role of single nucleotide polymorphisms of miRNAs 100 and 146a as prognostic factors for prostate cancer

et al. 2021

View full text Add to dashboard Cite

Introduction: Prostate cancer has a high incidence in men and is the second cause of cancer death among americans male. microRNA (miR) is becoming a potential new prognostic factor for prostate cancer. Single nucleotide polymorphisms (SNPs) are common polymorphisms, characterized by a single exchange of nitrogen based in the DNA. This polymorphism is present in the miRs, altering their function. Objective: To evaluate the role of SNP rs1834306 of miR100 and rs2910164 of miR146a in the development and prognosis of prostate cancer. Methods: One hundred patients diagnosed with prostate cancer and 68 controls were selected. The identification of SNP was rated by quantitative polymerase chain reaction from blood samples, and the analysis was performed within the presence of SNP and the prognostic variables. Results: In the SNP rs1834306 (miR100), a smaller presence of the polymorphic homozygous genotype was identified in patients with PSA >10 ng/mL, ( P=0.03); when evaluating only the presence of the polymorphic allele G ( P=0.09) it was compared to the presence of the wild type allele A. Among the patients with prostate cancer, SNP rs2910164 (miR146A), the polymorphic allele was more frequent in patients with a Gleason score ⩾7 than in patients with a Gleason score <7, ( P=0.043). In patients with prostate cancer, miR100 was overexpressed in those with pT3 staging compared to pT2 and among those who had biochemical recurrence ( P = 0.004 and P = 0.011, respectively). Conclusions: SNP of miR146a acts as a poor prognostic factor (Gleason ⩾7), and the SNP of miR100 is linked to better prognostic data (PSA <10). MiR100 was overexpressed in prostate cancer with worse prognostic factors.

show abstract

Section: Discussionsupporting

confidence: 60%

The role of single nucleotide polymorphisms of miRNAs 100 and 146a as prognostic factors for prostate cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…An elevated level of miR-100-5p in the A2780PR2 cell line seems to be related to PAC resistance. This miR was also observed in PAC-resistant prostate cancer cell lines [ 64 ] and ovarian cancer tissue [ 65 ]. Downregulation of miR-10a-5p in the A2780PR1 cell line may be related to PAC resistance in ovarian cancer, as we previously also observed downregulation of miR-10a-5p expression in two other PAC-resistant ovarian cancer cell lines [ 32 ].…”

Section: Discussionmentioning

confidence: 74%

The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines

Kaźmierczak

Jopek

Sterzyńska

et al. 2022

IJMS

View full text Add to dashboard Cite

Ovarian cancer is the most lethal gynecological malignancy. The high mortality results from late diagnosis and the development of drug resistance. Drug resistance results from changes in the expression of different drug-resistance genes that may be regulated miRNA. The main aim of our study was to detect changes in miRNA expression levels in two cisplatin (CIS) and two paclitaxel (PAC)—resistant variants of the A2780 drug-sensitive ovarian cancer cell line—by miRNA microarray. The next goal was to identify miRNAs responsible for the regulation of drug-resistance genes. We observed changes in the expression of 46 miRNA that may be related to drug resistance. The overexpression of miR-125b-5p, miR-99a-5p, miR-296-3p, and miR-887-3p and downregulation of miR-218-5p, miR-221-3p, and miR-222-3p was observed in both CIS-resistant cell lines. In both PAC-resistant cell lines, we observed the upregulation of miR-221-3p, miR-222-3p, and miR-4485, and decreased expression of miR-551b-3p, miR-551b-5p, and miR-218-5p. Analysis of targets suggest that expression of important drug-resistant genes like protein Tyrosine Phosphatase Receptor Type K (PTPRK), receptor tyrosine kinase—EPHA7, Semaphorin 3A (SEMA3A), or the ATP-binding cassette subfamily B member 1 gene (ABCB1) can be regulated by miRNA.

show abstract

“…Several miRNAs have been reported as upregulated in three paclitaxel-resistant cell lines, including miR-200b-3p, miR-375, and miR-34b-3p. In addition, the downstream genes of miRNAs, LARP1, and CCND1 are increased in paclitaxel-resistant cell lines, which could be the potential cause of resistance 32 . It has been found that miR199a, which is downregulated in prostate cancer tissues, is suppressed in PTX-resistance cell lines.…”

Section: Microrna and Drug Resistancementioning

confidence: 99%

Role of noncoding RNA in drug resistance of prostate cancer

et al. 2021

View full text Add to dashboard Cite

Prostate cancer is one of the most prevalent forms of cancer around the world. Androgen-deprivation treatment and chemotherapy are the curative approaches used to suppress prostate cancer progression. However, drug resistance is extensively and hard to overcome even though remarkable progress has been made in recent decades. Noncoding RNAs, such as miRNAs, lncRNAs, and circRNAs, are a group of cellular RNAs which participate in various cellular processes and diseases. Recently, accumulating evidence has highlighted the vital role of non-coding RNA in the development of drug resistance in prostate cancer. In this review, we summarize the important roles of these three classes of noncoding RNA in drug resistance and the potential therapeutic applications in this disease.

show abstract

Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines

Cited by 25 publications

References 34 publications

The role of single nucleotide polymorphisms of miRNAs 100 and 146a as prognostic factors for prostate cancer

The role of single nucleotide polymorphisms of miRNAs 100 and 146a as prognostic factors for prostate cancer

The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines

Role of noncoding RNA in drug resistance of prostate cancer

Contact Info

Product

Resources

About